论文部分内容阅读
目的利用疑似预防接种异常反应(Adverse Events Following Immunization,AEFI)监测数据探究是否有必要对广东省卡介苗(Bacille Calmette-Guerin,BCG)接种月龄进行推迟调整。方法通过广东省免疫规划信息管理系统和全国AEFI信息管理系统,收集2009~2014年广东省BCG接种数及AEFI个案数据。采用描述性方法对不同接种月龄的不良反应报告发生率等指标进行分析。结果广东省共报告2009~2014年接种BCG后AEFI 511例,报告发生率为44.18/100万剂;其中不良反应456例(89.24%),报告发生率为39.43/100万剂;不良反应以直径>1.0cm的淋巴结炎最常见(138例,11.93/100万剂);全身播散性BCG感染罕见(2例,0.17/100万剂)。在儿童<1月龄、≥1月龄接种BCG后淋巴结炎报告数分别为118例(11.67/100万剂)、20例(13.72/100万剂)。结论基于AEFI监测数据,没有足够证据表明需要推迟BCG接种月龄,应继续维持新生儿BCG免疫策略。
Objective To investigate whether it is necessary to postpone the adjustment of the age of inoculation of bacille Calmette-Guerin (BCG) in Guangdong Province by using the data of AEFI. Methods Guangdong immunization planning information management system and national AEFI information management system were used to collect data on BCG inoculation and AEFI in Guangdong from 2009 to 2014. Descriptive methods were used to analyze the incidence of adverse reactions such as age at month of inoculation. Results A total of 511 cases of AEFI were reported in Guangdong province from 2009 to 2014 after BCG immunization. The reported incidence was 44.18 / 1 million doses. Among them, 456 (89.24%) were adverse reactions, with a reported incidence of 39.43 / Lymphitis> 1.0 cm was most common (138, 11.93 / 1 million doses); disseminated BCG infection was rare (2, 0.17 / 1 million doses). The number of reports of lymphadenitis was 118 (11.67 / 1 million doses) and 20 (13.72 / 1 million doses) post-BCG vaccination in children <1 month of age. Conclusion Based on the AEFI surveillance data, there is insufficient evidence to demonstrate the need to postpone the BCG vaccination month and should continue to maintain the neonatal BCG immunization strategy.